Harnessing the power of the gut and the gut-brain axis holds enormous, transformational potential to improve human health. We are currently advancing a diverse portfolio of novel, oral small-molecule therapies across three areas: metabolism, neurological disorders, and gastrointestinal (GI) disease.
Therapeutic Areas of Focus
We are advancing a novel, oral approach to type 2 diabetes and obesity, two conditions of epidemic proportions in need of improved treatment options. Our platform enables rational, combinatorial approaches to induce secretion of a full spectrum of satiety hormones rather than targeting just one.
We have made significant advances using our proprietary Human Genetics Platform to identify multiple targets for neurological disorders, including migraine. We continue to focus our research efforts on therapeutic areas of high unmet need.
We are advancing novel, oral, non-immunosuppressive therapeutics to address diseases of the GI barrier and diseases of GI immunity, including celiac and food allergy. Our multi-targeted approach involves improving epithelial cell homeostasis, restoring appropriate immune responses, and repairing secretory cell function.